<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210519051341N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-23</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>A comparison between the Effectiveness of two different oral pastes, Containing Triamcinolone and Licorice, on minor Aphthous lesions: A triple blind randomized clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>A comparison between the Effectiveness of two different Oral pastes, containing Triamcinolone and Licorice, on Minor Aphthous lesions: A triple blind randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57221</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into three treatment groups A,  B, C using the Balance block randomization method, the size of each block is 6 and the total number of blocks is 10.
Balanced randomization allocation method for participants, in a randomized clinical trial study of the effect of Oral paste, containing Triamcinolone (group A), placebo (group B) and Licorice(group C) in reducing the size, pain and healing duration of the lesion.
Randomization unit: individual
Randomization tool: based on statistical software, Blinding description: These patients are divided into three groups of triamcinolone, Licorice and placebo (10 blocks of 6) based on random allocation.
Patients in the first group are given triamcinolone gel under the brand name Triadent 10 grams (from Raha Daroo Company) three times a day, the second group is given an oral gel containing Licorice and the third group is given a placebo gel.
The containers in which the drugs are placed are very similar to each other and the contents are unknown. This study is triple blind and the patient, researcher and statistician are unaware of the type of drug which is given.</study_design>
      <phase>3</phase>
      <hc_freetext>Recurrent oral Aphthae.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in the intervention group receive a drug containing the Licorice active ingredient. They are trained to apply the gel on the Aphthous lesion 3 times a day after brushing and to avoid eating and drinking for half an hour after that. The drug consists of the Licorice active ingredient with 5% concentration and Carboxymethyl Cellulose (CMC). Intervention 2: Standard treatment group: Triamcinolone (Trident 0.1%) is used as standard treatment. They should apply the oral paste on the Aphthous lesion 3 times a day after brushing and avoid eating and drinking for half an hour after that. Intervention 3: Control group: This group receives a placebo (containing no active substance). The placebo only consists of Carboxymethyl Cellulose (CMC). They should apply the placebo gel on the Aphthous lesion 3 times a day after brushing and avoid eating and drinking for half an hour after that.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahdie Zarabadipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Oral and maxillofacial medicine, school of dentistry, Qazvin University of Medical Sciences, Bahonar Blv, Qazvin</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3419915315</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>mzarabadipour@qums.ac.ir</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahdie Zarabadipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Oral and maxillofacial medicine, school of dentistry, Qazvin University of Medical Sciences, Bahonar Blv, Qazvin</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3419915315</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>mzarabadipour@qums.ac.ir</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with Minor Aphthous ulcers who have been visited within the first 24 hours of incidence of the lesion.
Patients do not have any systemic diseases ( Hypertension, Diabetes, Hyperlipidemia, Behcet disease, Rheumatism disease)
Don't use medicine, cigarettes, alcohol and addiction</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>An oral ulcer that is not an Aphthous lesion
More than 48hrs passed from incidence of the lesion
Allergic to herbal medicines
Use of medicine, cigarettes, alcohol and addiction
Systemic diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Recurrent oral Aphthae</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in the intervention group receive a drug containing the Licorice active ingredient. They are trained to apply the gel on the Aphthous lesion 3 times a day after brushing and to avoid eating and drinking for half an hour after that. The drug consists of the Licorice active ingredient with 5% concentration and Carboxymethyl Cellulose (CMC).</i_keyword>
      <i_keyword>Standard treatment group: Triamcinolone (Trident 0.1%) is used as standard treatment. They should apply the oral paste on the Aphthous lesion 3 times a day after brushing and avoid eating and drinking for half an hour after that.</i_keyword>
      <i_keyword>Control group: This group receives a placebo (containing no active substance). The placebo only consists of Carboxymethyl Cellulose (CMC). They should apply the placebo gel on the Aphthous lesion 3 times a day after brushing and avoid eating and drinking for half an hour after that.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Amount of pain. Timepoint: Before taking oral paste and the third, fifth and seventh days of treatment. Method of measurement: On the visit days, we ask the patient to mark the amount of pain on the Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Healing duration. Timepoint: Before taking oral paste and the third, fifth and seventh days of treatment. Method of measurement: Days spent until complete healing of the lesion.</prim_outcome>
      <prim_outcome>Size of the lesion. Timepoint: Before taking oral paste and the third, fifth and seventh days of treatment. Method of measurement: The largest diameter of the lesion is measured with the dental probe in millimetres.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-08-30</approval_date>
        <contact_name>Ethics committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>Qazvin University of Medical Sciences, Bahonar Blv, Qazvin Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
